000999 China Resources Sanjiu Medical & Pharmaceutical
- 60.93
- +0.58+0.96%
China Resources Sanjiu Medical & Pharmaceutical News
Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has
Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has maintained a positive development trend; 2) the integration work of the Kunyao Group is progressing steadily; 3) Continued development or introduction of innovative drugs, improved innovative drugs, generic drugs, classic famous recipes, etc. (Mainichi Keizai Shimbun)
China Resources 39 (000999) Review Report: CHC Business Achieves Rapid Growth and Cost Optimization
On April 19, 2024, the company released its 2024 quarterly report. 2024Q1, the company achieved operating income of 7.294 billion yuan (+14.82%) and net profit to mother of 1,364 billion yuan (+18.4)
China Resources 39 (000999): Strong growth under a high base
1Q24 revenue, net non-net profit increased 15% year-on-year, 17%. The company announced 1Q24 revenue of 7.29 billion yuan (+15% yoy), net profit to mother of 1.36 billion yuan (+18% yoy), deducted non-net profit1
Express News | Fangzheng Securities: Branded OTC products+brand+channels have an obvious leading effect
China Resources 39 (000999): Outstanding performance, CHC business drives rapid growth
In the first quarter of 2024, the company's revenue was 7.294 billion yuan, up 14.82% year on year; net profit to mother was 1,364 billion yuan, up 18.49% year on year; net profit after deducting non-return to mother was 1,328 billion yuan, year on year
China Resources 39 (000999): Performance exceeds expectations, core products maintain a good growth trend
1Q24 results were higher than our expectations. The company announced 1Q24 results: revenue of 7.294 billion yuan (YoY +14.82%) and net profit to mother of 1,364 billion yuan (YoY +18.49%), slightly higher than our expectations
Zhongtai Securities released a research report on April 21 stating that it maintains China Resources 39 (000999.SZ) buying rating. The main reasons for the rating include: 1) Q1 had a good start, and the performance surpassed market expectations; 2) net i
Zhongtai Securities released a research report on April 21 stating that it maintains China Resources 39 (000999.SZ) buying rating. The main reasons for the rating include: 1) Q1 had a good start, and the performance surpassed market expectations; 2) net interest rates increased significantly, and contract liabilities remained high; 3) the effects of the integration of Kunyao are expected to begin to be released in 2024. (Mainichi Keizai Shimbun)
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
China Resources Pharmaceuticals (03320.HK): China Resources's net profit to mother was 1,364 billion yuan in the first quarter, up 18.49% year-on-year
Gelonghui, April 22丨China Resources Pharmaceutical (03320.HK) announced that China Resources 39 (000999.SZ) achieved operating income of 7.294 billion yuan in the first quarter of 2024, up 14.82% year on year; net profit attributable to shareholders of China Resources 39 billion yuan, up 18.49% year on year; net profit attributable to China Resources 39 shareholders after deducting non-recurring profit and loss was 1,328 billion yuan, up 17.38% year on year; basic earnings per share were 1.39 yuan.
China Resources 39 (000999): Performance exceeds expectations, endogenous growth is strong
Key investment events: China Resources 39 released its 2024 quarterly report. During the reporting period, it achieved revenue of 7.294 billion yuan (+14.82% year over year) and net profit to mother of 1,364 billion yuan (+18.49% year over year), after deducting non-return to mother
China Resources 39 (000999): Outstanding performance under a high base, Q1 performance growth exceeded expectations
Core view The company achieved total operating income of 7.294 billion yuan in Q1, an increase of 14.82% over the previous year; achieved net profit of 1,364 billion yuan, an increase of 18.49% over the previous year; achieved net profit without deduction of 13.2 billion yuan
China Resources 39 (000999): Strong demand for the cold category, fee control increases profitability
Guide to this report: The company released its 2024 quarterly report. The performance slightly exceeded expectations. Demand for core products was strong, fee control capabilities were further optimized, and revenue and profit achieved steady growth. Combined with the promotion of the integration of Chinese medicines, future performance is expected to continue to grow steadily
China Resources 39 (000999): Contract liabilities remained high in Q1 beyond expectations
Incident: The company released its 2024 quarterly report. During the reporting period, it achieved total revenue of 7.294 billion yuan, an increase of 14.82% over the previous year; achieved net profit of 1,364 billion yuan, an increase of 18.49% over the previous year; achieved net deductions
Express News | China Resources 39: Net profit for the first quarter was 1.36 billion yuan.
China Resources 39 (000999.SZ): It is expected that the net interest rate level of KPC will gradually increase in the future
Gelonghui April 16 丨 China Resources 39 (000999.SZ) recently conducted an investor relations campaign on “Is there room for improving the profit margin of Kunyao?” The company replied that with the gradual focus of KPC's business and the improvement of the level of refined management, it is expected that the net interest rate level of KPC will gradually increase in the future.
Express News | China Resources 39: The company is expected to achieve double-digit revenue growth in 2024
China Resources 39 (000999.SZ): The cold breathing category accounts for the highest share of the company's CHC business
Gelonghui, April 16丨China Resources 39 (000999.SZ) recently conducted an investor relations campaign on “What is the share of the cold category in the CHC business sector and the growth forecast for the cold category in 24 years?” The company replied that the company's cold breathing category accounts for the highest share of the company's CHC business. The cold breathing category has grown rapidly in recent years. The company will continue to seize the opportunity and is expected to continue to grow steadily for 24 years.
Social Security Fund A share investment roadmap: OCT A and China Resources have both held positions for over 12 years. The list of long-term holdings is here
① The disclosure of the annual reports of A-share listed companies is in full swing. According to the latest data, social security funds appeared on the list of the top ten tradable shareholders of 257 listed companies. ② Looking at it over a long period of time, OCT A has been held by the Social Security Fund for the longest time, with China Resources 39 ranking second; ③ sort out the list of individual stocks held by the Social Security Fund for more than 10 years (attached table).
China Resources 39 (000999.SZ): As of March 20, the total number of shareholders of the company was 36,919
Gelonghui, April 10 | China Resources 39 (000999.SZ) said on the investor interactive platform that as of March 20, the total number of shareholders of the company was 36,919.
Express News | China Resources 39: Mergers and acquisitions will be strengthened in the future
Analysis
Price Target
No Data
